NCT04352400View on ClinicalTrials.gov

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
COVID19
Interventions
DRUG

Nafamostat Mesilate

administered intravenously as a continuous infusion

DRUG

Placebo

administered intravenously as a continuous infusion

Trial Locations (1)

35128

RECRUITING

Azienda Ospedale Università di Padova, Padua

All Listed Sponsors
collaborator

Yokohama City University

OTHER

collaborator

University of Zurich

OTHER

lead

University Hospital Padova

OTHER